Terms: = Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791 AND Treatment
3236 results:
1. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in leukemia and Lymphoma Cells In Vitro.
Wilke N; Frias C; Berkessel A; Prokop A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731935
[TBL] [Abstract] [Full Text] [Related]
2. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of the
Nasr GM; Thawabieh OM; Talaat RM; Moawad M; El Hamshary MO
Front Biosci (Landmark Ed); 2024 Apr; 29(4):162. PubMed ID: 38682177
[TBL] [Abstract] [Full Text] [Related]
4. Improved Survival of Patients With Chronic Lymphocytic leukemia Between 1998-2022, Including the Era of Target Therapies With bcl2 and BTK Inhibitors.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
[TBL] [Abstract] [Full Text] [Related]
5. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
[TBL] [Abstract] [Full Text] [Related]
6. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
7. [Effect of Shikonin on Autophagy and Apoptosis of Human Promyelocytic leukemia Cells].
Chen Y; Xie XM; Zhang XL; Zhang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):416-421. PubMed ID: 38660845
[TBL] [Abstract] [Full Text] [Related]
8. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
9. A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor.
Zhao W; Mo M; Yu J; Cheng S; Long G; Luo Z; Liang W; Yan C; Luo H; Sun B
Med Oncol; 2024 Apr; 41(5):113. PubMed ID: 38602586
[TBL] [Abstract] [Full Text] [Related]
10. Targeting Myeloid leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract] [Full Text] [Related]
12. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
Liu Y; Zhang S; Tan Y
Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
[No Abstract] [Full Text] [Related]
13. [Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].
Osada Y; Kanai-Sudo H; Mizuki T; Tanosaki S; Suzuki K
Rinsho Ketsueki; 2024; 65(3):135-141. PubMed ID: 38569855
[TBL] [Abstract] [Full Text] [Related]
14. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
[TBL] [Abstract] [Full Text] [Related]
15. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract] [Full Text] [Related]
16. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
Muthiah C; Narra R; Atallah E; Juan W; Szabo A; Guru Murthy GS
Leuk Res; 2024 May; 140():107496. PubMed ID: 38547577
[TBL] [Abstract] [Full Text] [Related]
17. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
18. Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
Xu J; Zong S; Sheng T; Zheng J; Wu Q; Wang Q; Tang A; Song Y; Fei Y; Li Z
Int J Hematol; 2024 May; 119(5):541-551. PubMed ID: 38530586
[TBL] [Abstract] [Full Text] [Related]
19. Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and bcl2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + bcl2 inhibitor venetoclax.
Li D; Yuan Y; Meng C; Lin Z; Zhao M; Shi L; Li M; Ye D; Cai Y; He X; Ye H; Zhou S; Zhou H; Gao S
Clin Epigenetics; 2024 Mar; 16(1):48. PubMed ID: 38528641
[TBL] [Abstract] [Full Text] [Related]
20. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Rodriguez-Sevilla JJ; Ganan-Gomez I; Ma F; Chien K; Del Rey M; Loghavi S; Montalban-Bravo G; Adema V; Wildeman B; Kanagal-Shamanna R; Bazinet A; Chifotides HT; Thongon N; Calvo X; Hernández-Rivas JM; Díez-Campelo M; Garcia-Manero G; Colla S
Nat Commun; 2024 Mar; 15(1):2428. PubMed ID: 38499526
[TBL] [Abstract] [Full Text] [Related]
[Next]
